Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

200%

4 of 2 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04051242Not ApplicableTerminated

Enhanced Bioscaffold for Volumetric Muscle Loss

Role: lead

NCT04601532Phase 4Terminated

Superficial Partial-Thickness Burn Study

Role: lead

NCT02076022Not ApplicableCompleted

AMP30: Autologous Fat Grafting, Amputation Sites Pain: Randomized

Role: lead

NCT01924364Not ApplicableCompleted

Effect of Concentrating Endogenous Stromal Cells in the Fat Graft Using TGI Device

Role: lead

All 4 trials loaded